The three co-Founders of CorFlow, Dr. Robert S. Schwartz, Prof. Martin T. Rothman and Jon H. Hoem, are the inventors.
By issuing this patent, the US Patent Office has protected the CoFI™ technology until 2037 in the United States.
Dr. Schwartz commented on the newly issued patent: "This patent is an important cornerstone in CorFlow’s overall patent strategy. In addition to protecting the innovative method of treating microvascular obstruction, it also provides technology descriptions and methods for MVO diagnosis and treatment which will be pursued in the continuation filings following the grant of this patent."
CorFlow has filed multiple other patent applications in major markets including the United States, Europe, China and Japan. These patent applications seek to protect the CorFlow diagnostic MVO measurements in the cath lab as well as additional technology implementations of the CoFI™ System. The company is very optimistic about securing patent rights in the targeted markets, thus building a solid IP portfolio for it’s business. CorFlow is represented by two leading US medical device patent offices based in Minneapolis (MN, USA).
CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as heart failure. The CorFlow technologies will enable interventional cardiologists to treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.
Caution: The CorFlow Controlled Flow Infusion (CoFITM) technology is in the early phases of development. It will not be available in Europe, the US or Japan for clinical trials until further notice and is NOT available for sale. This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CorFlow are based on management’s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, European or US Food and Drug Administration (FDA) approvals of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.
Copyright © 2016 – 2018 CorFlow Therapeutics AG. All rights reserved.
CorFlow Therapeutics AG
Telefon: +41 (79) 6062-902
CEO & Co-Founder
Telefon: +41 (41) 5445556